Navigation Links
ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
Date:3/16/2010

reclinical work and/or clinical activities to support regulatory filings, including prior to the filing or the approval of an NDA for ANX-530 and/or ANX-514, which activities may increase the cost and timeline to NDA filling or approval and negatively impact our ability to raise additional capital; the potential that changes made in transferring the manufacturing process for ANX-530 and ANX-514 may result in a lack of comparability between the commercial product and the material used in clinical trials, and that FDA may require ADVENTRX to perform additional non-clinical or clinical studies; the risk the FDA will determine that ANX-530 and Navelbine® and/or ANX-514 and Taxotere® are not bioequivalent, including as a result of performing pharmacokinetic equivalence analysis based on a patient population other than the population on which ADVENTRX based its analysis or determining that increased docetaxel blood-levels during and immediately following infusion are clinically relevant; the risk of investigator bias in reporting adverse events as a result of the open-label nature of the ANX-530 bioequivalence study; difficulties or delays in manufacturing, obtaining regulatory approval for and marketing ANX-530 and ANX-514, including validating commercial manufacturing processes and manufacturers, as well as suppliers, and the potential for automatic injunctions regarding FDA approval of ANX-514; ADVENTRX's reliance on the performance of third parties to assist in the conduct of its bioequivalence trials, regulatory submissions, CMC activities and other important aspects of the ANX-530 and ANX-514 development programs, including on-going stability studies for ANX-530 and analysis of the ANX-514 bioequivalence trial data, and that such third parties may fail to perform as expected; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission.  ADVENTRX's public filings w
'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. ADVENTRX Receives Brand Name Acceptance for ANX-530
2. ADVENTRX Receives Refuse to File Letter from FDA on ANX-530 New Drug Application
3. ADVENTRX Announces Management Promotions
4. ADVENTRX Appoints Icahn Representative to Board of Directors
5. ADVENTRX Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference on February 9
6. ADVENTRX Pharmaceuticals to Present at the Lippert/Heilshorn Life Sciences Virtual Conference
7. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
8. ADVENTRX Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26
9. ADVENTRX Pharmaceuticals Announces Closing of Financing
10. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 Legislation backed by the drugstore ... Pharmacies Act of 2014") championing so-called "any willing ... the availability of lower cost preferred pharmacy networks ... the next 10 years, according to new research ... Care Management Association (PCMA). The drugstore ...
(Date:7/22/2014)... , July 22, 2014  Eyeon Therapeutics has received ... treatment based on a charged hydrophilic polymer developed at ... has been shown to be safe and effective in ... MD, CEO states, "This first set of claims around ... way to moving this technology into the commercial phase.  ...
(Date:7/22/2014)... Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and ... lots of Fluzone ® (Influenza Vaccine) for the 2014-2015 ... Food and Drug Administration (FDA) for distribution. The lots were ... least 65 million doses of seasonal influenza vaccine manufactured by ... providers and pharmacies in August. The U.S. ...
Breaking Medicine Technology:New Study: H.R. 4577 to Cost $21 Billion over 10 Years 2New Study: H.R. 4577 to Cost $21 Billion over 10 Years 3Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7
... Aug. 17 The hospital patient room of the future ... New Jersey, providing lessons that stand to benefit hospitals and ... building a new hospital in Plainsboro, NJ, to replace its ... a fully functioning replica of the new hospital,s proposed patient ...
... Inc. (NYSE Amex: ULU ) today announced its financial ... the second quarter of 2010, the Company reported a net loss of ... $2.9 million, or $0.04 per share, for the same period last year. ... net loss of $3.5 million, or $0.04 per share, compared with a ...
Cached Medicine Technology:Hospital Room of the Future Debuts in New Jersey 2Hospital Room of the Future Debuts in New Jersey 3Hospital Room of the Future Debuts in New Jersey 4ULURU Inc. Reports Second Quarter 2010 Financial Results 2ULURU Inc. Reports Second Quarter 2010 Financial Results 3ULURU Inc. Reports Second Quarter 2010 Financial Results 4ULURU Inc. Reports Second Quarter 2010 Financial Results 5ULURU Inc. Reports Second Quarter 2010 Financial Results 6
(Date:7/22/2014)... Dr. Dental is excited to announce the ... visitors in mind, one of the main differences from the ... makes navigation very easy. Dr. Dental is renowned for having ... the dentist affordable, convenient and fun, and the new website ... an appointment scheduling system right on the home page where ...
(Date:7/22/2014)... 22, 2014 The 2014 Warrior-Family ... Ronald Reagan Building and International Trade Center in ... Families and Civilian Communities,” will be held from ... 7:30 a.m.) and cohosted by the Military Officers ... Industrial Association (NDIA). USAA is the Executive Sponsor ...
(Date:7/22/2014)... Aaron Marshall, Corporate Counsel at Northrop Grumman, will serve ... for the 2014-2015 fiscal year. He joined the Board ... "“Serving on the HASA board has given me a broader, ... remember how much others need help." , ABOUT AARON MARSHALL:, ... a B.S. in Finance from the University of Delaware. Currently, ...
(Date:7/22/2014)... Steven Reinberg HealthDay ... Two treatments that break up blood clots deep in the ... death risk. However, one results in a greater risk of ... cost of the other treatment, a new study finds. ... vein thrombosis (DVT) -- is blood-thinning medications and compression stockings. ...
(Date:7/22/2014)... The American Society of Hematology (ASH) will honor ... Los Angeles with the 2014 E. Donnall Thomas ... the discovery of the iron-regulatory hormone hepcidin and investigation ... after the Nobel Prize Laureate and past Society president ... hematology that have represented a paradigm shift or significant ...
Breaking Medicine News(10 mins):Health News:Dr. Dental Reveals Exciting New Website 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:New Board President for Baltimore-based Nonprofit 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3
... pretext for multinational corporations to take control of the precious ... With sales of over $35 billion worldwide in the ... buy up pristine springs in some of the country's most ... one-third of the U.S. market and sells 70 different brand ...
... overdose during pregnancy could be harmful, according to an Iranian ... combat anemia in pregnancy but many women take extra iron. ... carry enough oxygen due to low number of red blood ... carry normal amounts of oxygen. Common symptoms of anemia include ...
... for Inclusive Communities (CAIC) has recently joined the fight ... the majority of state and national disability rights organizations ... group that works on behalf of groups with developmental ... as a new national AP/Ipsis poll was released indicating ...
... the Pharmaceutical Research and Manufacturers of America (PhRMA) finds ... of the three leading causes of death of Americans ... currently in clinical trials or under review by the ... and stroke are still leading causes of death in ...
... advent of a possible new blockbuster drug and greater ... drug addictions, global sales of smoking cessation and ... little over $1.1 billion in 2005 to more than ... Addiction Treatments: A World Market Analysis, a new study ...
... on cardiometabolic risk factors beyond those expected from weight ... not be due to the drug itself, reports an ... Bulletin (DTB). ,Advertisements for rimonabant (sold ... an estimated 50% of the effects on cardiometabolic ...
Cached Medicine News:Health News:Multinationals Exploit Groundwater Sources, and People Suffer 2Health News:Multinationals Exploit Groundwater Sources, and People Suffer 3Health News:Multinationals Exploit Groundwater Sources, and People Suffer 4Health News:Multinationals Exploit Groundwater Sources, and People Suffer 5Health News:More Than 270 Medicines in Testing for Heart Disease and Stroke 2Health News:Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned 2
... matrix constructed of cross-linked collagen fibers ... through a proprietary 360 accretion process. ... aspirate, Healos provides an excellent environment ... differentiation. The hydroxyapatite-coated collagen microfibers in ...
Sharp Weitlaner Retractor....
Weitlaner retractor, blunt....
Bruns (Volkmann) bone curette, with Novotex plastic handle (autoclavable in autoclave up to 143C by 3 bar), 9, oval....
Medicine Products: